|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karaman B, Battal B, Sari S and Verim S:
Hepatocellular carcinoma review: Current treatment, and
evidence-based medicine. World J Gastroenterol. 20:18059–18060.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolf SS: The protein arginine
methyltransferase family: An update about function, new
perspectives and the physiological role in humans. Cell Mol Life
Sci. 66:2109–2121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pal S, Vishwanath SN, Erdjument-Bromage H,
Tempst P and Sif S: Human SWI/SNF-associated PRMT5 methylates
histone H3 arginine 8 and negatively regulates expression of ST7
and NM23 tumor suppressor genes. Mol Cell Biol. 24:9630–9645. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pal S, Baiocchi RA, Byrd JC, Grever MR,
Jacob ST and Sif S: Low levels of miR-92b/96 induce PRMT5
translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO
J. 26:3558–3569. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hou Z, Peng H, Ayyanathan K, Yan KP,
Langer EM, Longmore GD and Rauscher FJ III: The LIM protein AJUBA
recruits protein arginine methyltransferase 5 to mediate
SNAIL-dependent transcriptional repression. Mol Cell Biol.
28:3198–3207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Pal S and Sif S: Protein arginine
methyltransferase 5 suppresses the transcription of the RB family
of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol.
28:6262–6277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stopa N, Krebs JE and Shechter D: The
PRMT5 arginine methyltransferase: Many roles in development, cancer
and beyond. Cell Mol Life Sci. 72:2041–2059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jansson M, Durant ST, Cho EC, Sheahan S,
Edelmann M, Kessler B and La Thangue NB: Arginine methylation
regulates the p53 response. Nat Cell Biol. 10:1431–1439. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Z, Zheng L, Xu H, Dai H, Zhou M,
Pascua MR, Chen QM and Shen B: Methylation of FEN1 suppresses
nearby phosphorylation and facilitates PCNA binding. Nat Chem Biol.
6:766–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He W, Ma X, Yang X, Zhao Y, Qiu J and Hang
H: A role for the arginine methylation of Rad9 in checkpoint
control and cellular sensitivity to DNA damage. Nucleic Acids Res.
39:4719–4727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bandyopadhyay S, Harris DP, Adams GN,
Lause GE, McHugh A, Tillmaand EG, Money A, Willard B, Fox PL and
Dicorleto PE: HOXA9 methylation by PRMT5 is essential for
endothelial cell expression of leukocyte adhesion molecules. Mol
Cell Biol. 32:1202–1213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho EC, Zheng S, Munro S, Liu G, Carr SM,
Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, et al:
Arginine methylation controls growth regulation by E2F-1. EMBO J.
31:1785–1797. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar B, Yadav A, Brown NV, Zhao S,
Cipolla MJ, Wakely PE, Schmitt AC, Baiocchi RA, Teknos TN, Old M,
et al: Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor
outcome in oropharyngeal squamous cell carcinoma patients and is
inversely associated with p16-status. Oncotarget. 8:14847–14859.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanaka H, Hoshikawa Y, Oh-hara T, Koike S,
Naito M, Noda T, Arai H, Tsuruo T and Fujita N: PRMT5, a novel
TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis
via nuclear factor-kappaB activation. Mol Cancer Res. 7:557–569.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nicholas C, Yang J, Peters SB, Bill MA,
Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, et al: PRMT5 is
upregulated in malignant and metastatic melanoma and regulates
expression of MITF and p27(Kip1.). PLoS One. 8:e747102013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang B, Dong S, Zhu R, Hu C, Hou J, Li Y,
Zhao Q, Shao X, Bu Q, Li H, et al: Targeting protein arginine
methyltransferase 5 inhibits colorectal cancer growth by decreasing
arginine methylation of eIF4E and FGFR3. Oncotarget. 6:22799–22811.
2015.PubMed/NCBI
|
|
18
|
Zhang B, Dong S, Li Z, Lu L, Zhang S, Chen
X, Cen X and Wu Y: Targeting protein arginine methyltransferase 5
inhibits human hepatocellular carcinoma growth via the
downregulation of beta-catenin. J Transl Med. 13:3492015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shimizu D, Kanda M, Sugimoto H, Shibata M,
Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, et
al: The protein arginine methyltransferase 5 promotes malignant
phenotype of hepatocellular carcinoma cells and is associated with
adverse patient outcomes after curative hepatectomy. Int J Oncol.
50:381–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Prabhu L, Wei H, Chen L, Demir Ö, Sandusky
G, Sun E, Wang J, Mo J, Zeng L, Fishel M, et al: Adapting AlphaLISA
high throughput screen to discover a novel small-molecule inhibitor
targeting protein arginine methyltransferase 5 in pancreatic and
colorectal cancers. Oncotarget. 8:39963–39977. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim BY, Suh KS, Lee JG, Woo SR, Park IC,
Park SH, Han CJ, Kim SB, Jeong SH, Yeom YI, et al: Integrated
analysis of prognostic gene expression profiles from hepatitis B
virus-positive hepatocellular carcinoma and adjacent liver tissue.
Ann Surg Oncol. 19 Suppl 3:S328–S338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim BY, Choi DW, Woo SR, Park ER, Lee JG,
Kim SH, Koo I, Park SH, Han CJ, Kim SB, et al:
Recurrence-associated pathways in hepatitis B virus-positive
hepatocellular carcinoma. BMC Genomics. 16:2792015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park ER, Kim SB, Lee JS, Kim YH, Lee DH,
Cho EH, Park SH, Han CJ, Kim BY, Choi DW, et al: The mitochondrial
hinge protein, UQCRH, is a novel prognostic factor for
hepatocellular carcinoma. Cancer Med. 6:749–760. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seftor RE, Seftor EA, Gehlsen KR,
Stetler-Stevenson WG, Brown PD, Ruoslahti E and Hendrix MJ: Role of
the alpha v beta 3 integrin in human melanoma cell invasion. Proc
Natl Acad Sci USA. 89:1557–1561. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brooks PC, Strömblad S, Sanders LC, von
Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and
Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the
surface of invasive cells by interaction with integrin alpha v beta
3. Cell. 85:683–693. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muschel RJ and Yong J: The Gelatinases,
MMP-2 and MMP-9-Implications for invasion and metastasisProteases
and Their Inhibitors in Cancer Metastasis. Foidart JM and Muschel
RJ: Springer Netherlands; Dordrecht: pp. 39–52. 2002, View Article : Google Scholar
|
|
27
|
Wu Y, Wang Z, Zhang J and Ling R: Elevated
expression of protein arginine methyltransferase 5 predicts the
poor prognosis of breast cancer. Tumour Biol.
39:10104283176959172017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanda M, Shimizu D, Fujii T, Tanaka H,
Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, et
al: Protein arginine methyltransferase 5 is associated with
malignant phenotype and peritoneal metastasis in gastric cancer.
Int J Oncol. 49:1195–1202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chung J, Karkhanis V, Tae S, Yan F, Smith
P, Ayers LW, Agostinelli C, Pileri S, Denis GV, Baiocchi RA, et al:
Protein arginine methyltransferase 5 (PRMT5) inhibition induces
lymphoma cell death through reactivation of the retinoblastoma
tumor suppressor pathway and polycomb repressor complex 2 (PRC2)
silencing. J Biol Chem. 288:35534–35547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y,
Du X, Li J, Li P, Ren R, et al: Targeting methyltransferase PRMT5
eliminates leukemia stem cells in chronic myelogenous leukemia. J
Clin Invest. 126:3961–3980. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu Z, Li Y, Lee P, Liu T, Wan C and Wang
Z: Protein arginine methyltransferase 5 functions in opposite ways
in the cytoplasm and nucleus of prostate cancer cells. PLoS One.
7:e440332012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang HT, Zhang D, Zha ZG and Hu CD:
Transcriptional activation of PRMT5 by NF-Y is required for cell
growth and negatively regulated by the PKC/c-Fos signaling in
prostate cancer cells. Biochim Biophys Acta. 1839:1330–1340. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deng X, Shao G, Zhang HT, Li C, Zhang D,
Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J, et al: Protein
arginine methyltransferase 5 functions as an epigenetic activator
of the androgen receptor to promote prostate cancer cell growth.
Oncogene. 36:1223–1231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bao X, Zhao S, Liu T, Liu Y, Liu Y and
Yang X: Overexpression of PRMT5 promotes tumor cell growth and is
associated with poor disease prognosis in epithelial ovarian
cancer. J Histochem Cytochem. 61:206–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shilo K, Wu X, Sharma S, Welliver M, Duan
W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL,
et al: Cellular localization of protein arginine
methyltransferase-5 correlates with grade of lung tumors. Diagn
Pathol. 8:2012013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen H, Lorton B, Gupta V and Shechter D:
A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through
histone H3 and H4 arginine methylation coupled transcriptional
activation and repression. Oncogene. 36:373–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen D, Zeng S, Huang M, Xu H, Liang L and
Yang X: Role of protein arginine methyltransferase 5 in
inflammation and migration of fibroblast-like synoviocytes in
rheumatoid arthritis. J Cell Mol Med. 21:781–790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saha K, Fisher ML, Adhikary G, Grun D and
Eckert RL: Sulforaphane suppresses PRMT5/MEP50 function in
epidermal squamous cell carcinoma leading to reduced tumor
formation. Carcinogenesis. 38:827–836. 2017. View Article : Google Scholar : PubMed/NCBI
|
